| Date | Title | Description |
| 13.09.2026 | Breakthrough Asthma Therapy: WIN378 Advances to Phase 3 with Promising Twice-Yearly Dosing | New asthma treatment WIN378 delivers strong Phase 2 results. This ultra-long-acting TSLP inhibitor, developed by Kelun-Biotech and Harbour BioMed, and advanced by Windward Bio, significantly improved lung function (FEV1) and reduced key inf... |
| 11.09.2026 | Key approvals, positive study results and a partnership deal to fast track new medications |
BioVersys, a multi-asset biotech company focused on the development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, has been granted Fast Track designation by the U.S. ... |
| 08.09.2026 | HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study | The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consisten... |
| 08.09.2026 | Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study | The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consisten... |
| 24.07.2026 | Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 24, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 09.06.2026 | Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378 | COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease
SKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026
... |
| 09.06.2026 | First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody | COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease
HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in... |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 05.05.2026 | Windward Bio secures USD 165 million to advance clinical trials |
WIN378, Windward's lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression ... |
| 05.05.2026 | Windward Bio raises USD 165M to advance new treatments for immune-related diseases | 05.05.2026 09:37, Rita Longobardi
Windward Bio, a clinical-stage biotechnology company focused on immune-related diseases, has raised USD 165 million in new funding. The company has been building its drug pipeline quickly since its launch i... |
| 30.03.2026 | Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year | TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximat... |
| 30.03.2026 | Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 24.03.2026 | KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF | Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.
R&D Expenses was approximately RMB1319.68 million.
Loss for the period was RMB381... |
| 16.01.2026 | Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference | CHENGDU, China, Jan. 16, 2026 /PRNewswire/ -- From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmace... |
| 12.01.2026 | Switzerland's Biotech Surge: Windward Bio Secures Funding, Forges Global Drug Deal Amidst Venturelab's Record Year | Swiss innovation is surging. Venturelab, a key accelerator, empowered over 6,700 entrepreneurs in 2025. It propelled Swiss startups to raise billions in funding. Biotech leader Windward Bio exemplified this success. The company secured a si... |
| 06.01.2026 | Windward Bio signs new licensing agreement to expand clinical pipeline |
Windward Bio, a clinical-stage biotechnology company, launched in early 2025 with a $200M Series A led by top-tier investors. The company is building a pipeline of long-acting bispecific antibodies, targeting validated biology in respirato... |
| 23.12.2025 | Venturelab 2025: Powering Over 6,700 Entrepreneurs | 23.12.2025 13:40, Rita Longobardi
2025 was a record-breaking year for Venturelab, delivering 544 days of training, workshops, and international programs to 6,700 entrepreneurs and driving Swiss startups to raise billions. From Venture Kick ... |
| 23.07.2025 | HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma | Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026
HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TS... |
| 23.07.2025 | Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378 | CHENGDU, China, July 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced that its partner, Windward Bio AG ("Windward Bio") ... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round |
Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 13.01.2025 | Windward Bio: Drug Development Company Raises $200 Million (Series A) | Novo Holdings, a leading life science investor, announced that it has invested in a $200 million Series A launch financing for Windward Bio. This oversubscribed financing was co-led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportu... |
| 11.01.2025 | A New Dawn in Immunotherapy: Harbour BioMed and Kelun-Biotech's Strategic Move with Windward Bio | In the fast-paced world of biopharmaceuticals, partnerships can be the lifeblood of innovation. The recent collaboration between Harbour BioMed, Kelun-Biotech, and Windward Bio marks a significant milestone in the development of immunologic... |
| 11.01.2025 | Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb). | CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "... |
| 10.01.2025 | Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of ... |
| 10.01.2025 | Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD | Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of its lead program and IN... |
| - | Windward Bio | “Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.” |
| - | Windward Bio | “Windward Bio” |
